MAPKs: new targets for neurodegeneration

Bibliography

• NICHOLSON DW: Apoptosis - baiting death inhibitors. Nature (2001) 410:33–34.
   PubMed Web of Science ®Google Scholar
• ROY S, NICHOLSON DW: Cross-talk in cell death signaling. J. Exp. Med. (2000) 192:F21–F25.
   Web of Science ®Google Scholar
• SALVESEN GS, DUCKETT CS: IAP proteins: blocking the road to death's door. Nat. Rev Mal Cell Biol. (2002) 3:401–410.
   PubMed Web of Science ®Google Scholar
• •Excellent recent review of cell death focusing on inhibitors of apoptosis.
   Google Scholar
• XIA Z, DICKENS M, RAINGEAUD J, DAVIS RJ, GREENBERG ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 270:1326–1331.
   PubMed Web of Science ®Google Scholar
• ••First report of the 'stress-activatedpathways' being activated and MAPK pathways being down-regulated in PC12 cells in response to NGF withdrawal. A key paper that initiated a field of research.
   Google Scholar
• CHANG L, KARIN M: Mammalian MAP kinase signalling cascades. Nature (2001) 410:37–40.
   PubMed Web of Science ®Google Scholar
• •Review of MAPK signalling pathways.
   Google Scholar
• COBB MH: MAP kinase pathways. Frog. Biophys. Mal Biol. (1999) 19:479–500.
   Google Scholar
• ROBINSON MJ, COBB MH: Mitogen-activated protein kinase pathways. Curr. Opin. Cell. Biol. (1999) 9:180–186.
   Web of Science ®Google Scholar
• SEGER R, KREBS EG: The MAPK signaling cascade. FASEB J. (1995) 9:726–735.
   PubMed Web of Science ®Google Scholar
• PETTMANN B, HENDERSON CE: Neuronal cell death. Neuron (1998) 20:633–647.
   PubMed Web of Science ®Google Scholar
• STANCIU M, WANG Y, KENTOR R etal.: Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. (2000) 275:12200–12206.
   Google Scholar
• FAVATA MF, HORIUCHI KY, MANOS EJ etal.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. Bia. Chem. (1998) 273:18623–18632.
   Google Scholar
• SATOH T, NAKATSUKA D, WATANABE Y et al.: Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci. Lett. (2000) 288:163–166.
   PubMed Web of Science ®Google Scholar
• SEO SR, CHONG SA, LEE SI et al: Zn2+-induced ERK activation mediated by reactive oxygen species causes cell death in differentiated PC12 cells. J. Neurochem. (2001) 78:600–610.
   PubMed Web of Science ®Google Scholar
• ALESSI DR, CUENDA A, COHEN P, DUDLEY DT, SALTIEL AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. (1995) 270:27489–27494.
   PubMed Web of Science ®Google Scholar
• FERRER I, BLANCO R, CARMONA M: Differential expression of active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates following quinolinic acid excitotoxicity in the rat. Mal Brain Res. (2001) 94:48–58.
   Web of Science ®Google Scholar
• ALESSANDRINI A, NAMURA S, MOSKOWITZ MA, BONVENTRE JV: MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sd. USA (1999) 96:12866–12869.
   PubMed Web of Science ®Google Scholar
• NAMURA S, IIHARA K, TAKAMI S etal.:Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc. Natl. Acad. Sd. USA (2001) 98:11569–11574.
   Google Scholar
• SLEVIN M, KRUPINSKI J, SLOWIK Aet al.: Activation of MAP kinase (ERK-1/ ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport (2000) 11:2759–2764.
   Google Scholar
• FERRER I, BLANCO R, CARMONA M et al.: Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural Transm. (2001) 108:1383–1396.
   PubMed Web of Science ®Google Scholar
• KULICH SM, CHU CT: Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. P Neuroc(2001) 77:1058–1066.
   PubMed Web of Science ®Google Scholar
• MURRAY B, ALESSANDRINI A, COLE AJ, YEE AG, FURSHPAN EJ: Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc. Natl. Acad. Sci. USA (1998) 95:11975–11980.
   PubMed Web of Science ®Google Scholar
• PERRY G, RODER H, NUNOMURA A, TAKEDA A etal.: Activation of neuronal extracellular receptor kinase (ERIK) in Alzheimer disease links oxidative stress to abnormal tau phosphorylation. Neuroreport (1999) 10:2411–2415.
   Google Scholar
• FERRER I, BLANCO R, CARMONA M et al: Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. (2001) 11:144–158.
   PubMed Web of Science ®Google Scholar
• HAN J, LEE JD, BIBBS L, ULEVITCH RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (1994) 265:808–811.
   PubMed Web of Science ®Google Scholar
• LEE JC, LAYDON JT, MCDONNELL PC et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739–746.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GRAM H, ZHAO M et al: Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38& P Biol. Chem. (1997) 272:30122–30128.
   Web of Science ®Google Scholar
• LI Z, JIANG Y, ULEVITCH RJ, HAN J: The primary structure of p38y a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. (1996) 228:334–340.
   PubMed Web of Science ®Google Scholar
• WANG XS, DIENER K, MANTHEY CL et al: Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. _J. Biol. Chem. (1997) 272:23668–23674.
   PubMed Web of Science ®Google Scholar
• IRVING EA, BARONE FC, REITH AD, HADINGHAM SJ, PARSONS AA: Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Mal Brain Res. (2000) 77:65–75.
   Web of Science ®Google Scholar
• WALTON KM, DIROCCO R, BARTLETT BA etal.: Activation of p38MAPK in microglia after ischemia. P Neurachern. (1998) 70:1764–1767.
   Google Scholar
• ONO K, HAN J: The p38 signal transduction pathway activation and function. Cell Signal (2000) 12:1–13.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH KA, KUMMER JL: Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons. j. Biol. Chem. (1996) 271:9891–9894.
   PubMed Web of Science ®Google Scholar
• HORSTMANN S, KAHLE PJ, BORASIO GD: Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro. j Neurosci. Res. (1998) 52:483–490.
   PubMed Web of Science ®Google Scholar
• KAWASAKI H, MOROOKA T, SHIMOHAMA S etal.: Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. P Biol. Chem. (1997) 272:18518–18521.
   Google Scholar
• CHENG HL, FELDMAN EL: Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-1. _J. Biol. Chem. (1998) 273:14560–14565.
   PubMed Web of Science ®Google Scholar
• HARPER SJ, LOGRASSO P: Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal (2001) 13:299–310.
   PubMed Web of Science ®Google Scholar
• MIELKE K, HERDEGEN T: JNK and p38 stress kinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol (2000) 61:45–60.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of SAPK signallingin the nervous system.
   Google Scholar
• MIELKE K, BRECHT S, DORST A, HERDEGEN T: Activity and expression of JNK1, p38 and erk kinases, c-Jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures. Neuroscience (1999) 91:471–483.
   PubMed Web of Science ®Google Scholar
• MARUYAMA M, SUDO T, KASUYA Y et al.: Immunolocalization of p38 MAP kinase in mouse brain. Brain Res. (2000) 887:350–358.
   PubMed Web of Science ®Google Scholar
• HENSLEY K, FLOYD RA, ZHENG NY et al.: p38 kinase is activated in the Alzheimer's disease brain. j Neurochem. (1999) 72:2053–2058.
   PubMed Web of Science ®Google Scholar
• KUMMER JL, RAO PK, HEIDENREICH KA: Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol. Chem. (1997) 272:20490–20494.
   PubMed Web of Science ®Google Scholar
• WATSON A, EILERS A, LALLEMAND D et al.: Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. Neurosci. (1998) 18:751–762.
   Web of Science ®Google Scholar
• HARADA J, SUGIMOTO M: An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. him I. Pharmacol (1999) 79:369–378.
   Web of Science ®Google Scholar
• KIKUCHI M, TENNETI L, LIPTON SA: Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. j Neurosci. (2000) 20:5037–5044.
   PubMed Web of Science ®Google Scholar
• •Good paper showing activation of p38 in retinal ganglion cells in response to optic nerve axotomy.
   Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. j Physiol Lung Cell. Mal Physiol (2000) 279:L895–L902.
   PubMed Web of Science ®Google Scholar
• WARD KW, PROKSCH JW, AZZARANO LM et al: SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharmaceut. Res. (2001) 18:1336–1344.
   PubMed Web of Science ®Google Scholar
• LEGOS JJ, MCLAUGHLIN B, SKAPER SD et al.: The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur j Pharmacol (2002) 447:37–42.
   PubMed Web of Science ®Google Scholar
• BARONE FC, IRVING EA, RAY AM et al: SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. j Pharm. Exp. Ther (2001) 296:312–321.
   PubMed Web of Science ®Google Scholar
• ••First publication of the effect of a specificp38 inhibitor in a model of cerebral ischaemia.
   Google Scholar
• LEGOS JJ, ERHARDT JA, WHITE RF et al: SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. (2001) 892:70–77.
   PubMed Web of Science ®Google Scholar
• LIN S, ZHANG Y, DODEL R et al: Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. (2001) 315:61–64.
   PubMed Web of Science ®Google Scholar
• •Paper showing that minocycline acts by inhibiting p38 MAPK.
   Google Scholar
• DU Y, MA Z, LIN S et al: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci USA (2001) 98:14669–14674.
   PubMed Web of Science ®Google Scholar
• VAN DEN BL, TILKIN P, LEMMENS G, ROBBERECHT W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13:1067–1070.
   PubMed Web of Science ®Google Scholar
• ZHU S, STAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74–78.
   PubMed Web of Science ®Google Scholar
• CHEN M, ONA VO, LI M et al: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. (2000) 6:797–801.
   PubMed Web of Science ®Google Scholar
• •This paper implicates caspases as the targets of minocycline.
   Google Scholar
• SANCHEZ-MEJIA RO, ONA VO, LI M, FRIEDLANDER RIVI: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery (2001) 48:1393–1399.
   PubMed Web of Science ®Google Scholar
• YRJANHEIKKI J, TIKKA T, KEINANEN R etal.: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Li. USA (1999) 96:13496–13500.
   Google Scholar
• YRJANHEIKKI J, KEINANEN R, PELLIKKA M et al: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Li. USA (1998) 95:15769–15774.
   PubMed Web of Science ®Google Scholar
• TIKKA T, FIEBICH BL, GOLDSTEINS G, KEINANEN R, KOISTINAHO J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. Neurosci. (2001) 21:2580–2588.
   PubMed Web of Science ®Google Scholar
• MOHIT AA, MARTIN JH, MILLER CA: p49 (3F12) kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron (1995) 14:67–78.
   PubMed Web of Science ®Google Scholar
• GIASSON BI, MUSHYNSKI WE: Aberrant stress-induced phosphorylation of perikaryal neurofilaments. I Biol. Chem. (1996) 271:30404–30409.
   Web of Science ®Google Scholar
• ZENTRICH E, HAN SY, PESSOA BL, BUTTERFIELD L, HEASLEY LE: Collaboration of JNKs and ERKs in nerve growth factor regulation of the neurofilament light chain promoter in PC12 cells. J. Biol. Chem. (2002) 277:4110–4118.
   PubMed Web of Science ®Google Scholar
• KUAN C: Jun kinase signaling and caspase-3 activation in neuronal apoptosis in ischemia-hypoxia. 31st Annual Meeting of the Society for Neuroscience, San Diego, California, USA. Soc. Neurosci. Abs. (2001) 27:30.
   Google Scholar
• MORISHIMA Y, GOTOH Y, ZIEG J et al: Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. j Neurosci. (2001) 21:7551–7560.
   PubMed Web of Science ®Google Scholar
• •Analysis of An-induced apoptotic signalling pathways in primary neuronal cultures derived from JNK-31- mice.
   Google Scholar
• BRUCKNER SR, TAMMARIELLO SP, KUAN CY et al.: JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. I Neurochem. (2001) 78:298–303.
   PubMed Web of Science ®Google Scholar
• YANG DD, KUAN CY, WHITMARSH AJ et al.: Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature (1997) 389:865–870.
   PubMed Web of Science ®Google Scholar
• ••A JNK-3 knockout mouse shows decreasedneuronal death and seizure activity following kainate administration.
   Google Scholar
• TROY CM, RABACCHI SA, XU Z et al: 3-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. Neurochem. (2001) 77:157–164.
   PubMed Web of Science ®Google Scholar
• BOZYCZKO CD, O'KANE TM, WU ZL et al: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with AP-induced cortical neuron apoptosis. j Neurochem. (2001) 77:849–863.
   PubMed Web of Science ®Google Scholar
• WEI W, NORTON DD, WANG X, KUSIAK JW: A13 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain (2002) 125:2036–2043.
   PubMed Web of Science ®Google Scholar
• PASSER B, PELLEGRINI L, RUSSO C et al: Generation of an apoptotic intracellular peptide by (gamma)-secretase cleavage of Alzheimer's amyloid (3) protein precursor. j Alzheimer's Dis. (2000) 2:289–301.
   PubMedGoogle Scholar
• DICKENS M, ROGERS JS, CAVANAGH J et al.: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 277:693–696.
   PubMed Web of Science ®Google Scholar
• SCHEINFELD MH, RONCARATI R, VITO P et al.: Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP). j. Biol. Chem. (2002) 277:3767–3775.
   PubMed Web of Science ®Google Scholar
• KINOSHITA A, WHELAN CM, BEREZOVSKA O, HYMAN BT: The 7 secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. j Biol. Chem. (2002) 277:28530–28536.
   PubMed Web of Science ®Google Scholar
• BUEE-SCHERRER V, GOEDERT M: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett (2002) 515:151–154.
   PubMed Web of Science ®Google Scholar
• ZHU X, ROTTKAMP CA, BOUX H, TAKEDA A et al.: Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. j Neuropathol Exp. Neural. (2000) 59:880–888.
   PubMed Web of Science ®Google Scholar
• ZHU X, RAINA AK, ROTTKAMP CA et al.: Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. j. Neurochern. (2001) 76:435–441.
   PubMed Web of Science ®Google Scholar
• ATZORI C, GHETTI B, PIVA R et al: Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. Neuropathol Exp. Neural. (2001) 60:1190–1197.
   PubMed Web of Science ®Google Scholar
• SAVAGE MJ, LIN YG, CIALLELLA JR,FLOOD DG, RICHARD W: Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. j Neurosci. (2002) 22:3376–3385.
   PubMed Web of Science ®Google Scholar
• GEARAN T, CASTILLO OA, SCHWARZSCHILD MA: The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergic neurons of mesencephalic cultures. Parkinsonism Relat. Disord. (2001) 8:19–22.
   PubMed Web of Science ®Google Scholar
• CHUN HS, GIBSON GE, DEGIORGIO LA et al: Dopaminergic cell death induced by MPPH, oxidant and specific neurotoxicants shares the common molecular mechanism. j Neurochem. (2001) 76:1010–1021.
   PubMed Web of Science ®Google Scholar
• CHOI WS, YOON SY, OH TH et al: Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP*-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. j Neurosci. Res. (1999) 57:86–94.
   PubMed Web of Science ®Google Scholar
• VAUDANO E, ROSENBLAD C, BJORKLUND A: Injury induced c-Jun expression and phosphorylation in the dopaminergic nigral neurons of the rat: correlation with neuronal death and modulation by glial-cell-line-derived neurotrophic factor. Eur. j Neurosci. (2001) 13:1–14.
   PubMed Web of Science ®Google Scholar
• SAPORITO MS, THOMAS BA, SCOTT RW: MPTP activates c-Jun NH2-terminal kinase (JNK) and its upstream regulatory kinase MIKK4 in nigrostriatal neurons in vivo. I Neurochem. (2000) 75:1200–1208.
   PubMed Web of Science ®Google Scholar
• ••Paper from the Cephalon group showingthat JNK is activated in the nigrostriatal system following a single injection of MPTP.
   Google Scholar
• XIA XG, HARDING T, WELLER M et al.: Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (2001) 98:10433–10438.
   PubMed Web of Science ®Google Scholar
• ••One of two papers (see 1851) publishedaround the same time, showing that inhibiting the JNK pathway using viral gene transfer methods inhibits both JNK activation and rescues neuronal cell loss. In this paper, JIP-1 scaffold protein was overexpressed in the MPTP model of PD.
   Google Scholar
• SAPORITO MS, BROWN EM, MILLER MS, CARSWELL S: CEP-1347/ KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. j. PharmacoL Esp. Ther. (1999) 288:421–427.
   PubMed Web of Science ®Google Scholar
• ••Paper from the Cephalon group showingthat CEP-1347 inhibits MPTP-induced dopaminergic neuronal cell death.
   Google Scholar
• CROCKER SJ, LAMBA WR, SMITH PD et al.: c-Jun mediates axotomy-induced dopamine neuron death PI vivo Proc. Natl. Acad. Sci. USA (2001) 98:13385–13390.
   PubMed Web of Science ®Google Scholar
• ••One of two papers (see 1831) showing thatexpression of a dominant-negative version of c-Jun in the nigrostriatal system protects against axotomy-induced cell death.
   Google Scholar
• GARCIA M, VANHOUTTE P, PAGES C et al.: The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. j. Neurosci. (2002) 22:2174–2184.
   PubMed Web of Science ®Google Scholar
• LIU YF: Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. j. Biol. Chem. (1998) 273:28873–28877.
   PubMed Web of Science ®Google Scholar
• LADIWALA U, LI H, ANTEL JP, NALBANTOGLU J: p53 induction by tumor necrosis factor-a and involvement of p53 in cell death of human oligodendrocytes. I Neurochem. (1999) 73:605–611.
   PubMed Web of Science ®Google Scholar
• ZHANG P, HOGAN EL, BRAT NR: Activation of JNK/SAPK in primary glial cultures: II. Differential activation of kinase isoforms corresponds to their differential expression. Neurochem. Res. (1998) 23:219–225.
   Google Scholar
• ZHANG P, MILLER BS, ROSENZWEIG SA, BHAT NR: Activation of C-jun N-terminal kinase/stress-activated protein kinase in primary glial cultures.Neurosci. Res. (1996) 46:114–121.
   Web of Science ®Google Scholar
• LIU HN, GIASSON BI, MUSHYNSKI WE, ALMAZAN G: AMPA receptor-mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase-3. I Neurochem. (2002) 82:398–409.
   PubMed Web of Science ®Google Scholar
• BONETTI B, STEGAGNO C, CANNELLA B etal.: Activation of NF-1cI3 and c-jun transcription factors in multiple sclerosis lesions - implications for oligodendrocyte pathology. Am. j Pathol. (1999) 155:1433–1438.
   Google Scholar
• HERDEGEN T, CLARET FX, KALLUNKI T et al.: Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. I Neurosci. (1998) 18:5124–5135.
   Web of Science ®Google Scholar
• SUGINO T, NOZAKI K, TAKAGI Y etal.: Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. I Neurosci. (2000) 20:4506–4514.
   Google Scholar
• TAKAGI Y, NOZAKI K, SUGINO T, HATTORI I, HASHIMOTO N: Phosphorylation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase after transient forebrain ischemia in mice. Neurosci. Lett. (2000) 294:117–120.
   PubMed Web of Science ®Google Scholar
• GU Z, JIANG Q, ZHANG G: Extracellular signal-regulated kinase and c-Jun N-terminal protein kinase in ischemic tolerance. Neuroreport (2001) 12:3487–3491.
   PubMed Web of Science ®Google Scholar
• GU Z, JIANG Q, ZHANG G: c-Jun N-terminal kinase activation in hippocampal CA1 region was involved in ischemic injury. Neuroreport (2001) 12:897–900.
   PubMed Web of Science ®Google Scholar
• SHACKELFORD DA, YEH RY: Differential effects of ischemia and reperfusion on c-Jun N-terminal kinase isoform protein and activity. Md. Brain Res. (2001) 94:178–192.
   PubMed Web of Science ®Google Scholar
• •Effects on JNK activation in a spinal cord model of ischaemia.
   Google Scholar
• HAYASHI T, SAKAI K, I, SASAKI C etal.: c-Jun N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion. Neurosci. Lett. (2000) 284:195–199.
   Google Scholar
• RAYMON HK, OMHOLT PE, CELERIDAD MT et al.: The JNK inhibitor, 5PC9766 is efficacious in models of epilepsy and stroke. 31st Ammal Meeting of the Society for Neuroscience, San Diego, California, USA. Soc. Neurosci. Abs. (2001) 27:1877.
   Google Scholar
• •First report to demonstrate the effect of Signal/Celgene's JNK inhibitor in models of stroke and epilepsy.
   Google Scholar
• COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev Drug Discov. (2002) 1:309–315.
   PubMed Web of Science ®Google Scholar
• ••Extensive review of kinase inhibitorscurrently in clinical development.
   Google Scholar
• BILSLAND J, ROY S, XANTHOUDAKIS S et al.: Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. I Neurosci. (2002) 22:2637–2649.
   Google Scholar
• TANG G, MINEMOTO Y, DIBLING B et al.: Inhibition of JNK activation through NF-1c13 target genes. Nature (2001) 414:313–317.
   PubMed Web of Science ®Google Scholar